alendronate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123456789101112»
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Fluffy hybrid nanoadjuvants for reversing the imbalance of osteoclastic and osteogenic niches in osteoporosis. (Pubmed Central) -  Jun 7, 2024   
    Despite the development of nationally recognized first-line anti-osteoporosis drugs, including alendronate (AL), their low bioavailability, poor uptake rate, and dose-related side effects present significant challenges in treatment...Therefore, this study constructed a drug nanoadjuvant with peculiar topological structures and high bone targeting capacities, efficient intracellular drug delivery as well as bone bioactivity. This provides a novel perspective on drug delivery for osteoporosis and treatment strategies for other bone diseases.
  • ||||||||||  Retrospective data, Review, Journal:  Dental Implant Failure in Post-Menopausal Women on Oral Bisphosphonates: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jun 5, 2024   
    Risedronate was used in 6 studies, while ibandronate was used in 4 studies...Overall, the qualitative assessment of this review suggests that oral treatment with BPs in post-menopausal women does not increase the rate of dental implant failure. Thus, further studies with larger sample sizes should compare BP and non-BP groups in regard to dental implants.
  • ||||||||||  alendronate / Generic mfg.
    Review, Journal:  From pill to pain: Alendronate-induced esophageal injury-A case report and review. (Pubmed Central) -  Jun 4, 2024   
    This case report is a timely reminder of the importance of thorough pharmacovigilance, patient education, and smart therapeutic decision-making in the context of alendronate use. To properly treat and prevent problems with the esophagus caused by alendronate, additional research is required.
  • ||||||||||  MALE OSTEOPOROSIS: EPIDEMIOLOGICAL, CLINICAL AND ETIOLOGICAL PROFILE () -  May 29, 2024 - Abstract #EULAR2024EULAR_4438;    
    To properly treat and prevent problems with the esophagus caused by alendronate, additional research is required. The most frequent etiologies were prolonged general corticosteroid therapy (43.7%) with a mean daily dose of 14 mg prednisone equivalent for a mean duration of 7.5
  • ||||||||||  zoledronic acid / Generic mfg.
    DENSITOMETRIC GAIN UNDER ZOLEDRONATE: ILLUSION OR REALITY? () -  May 29, 2024 - Abstract #EULAR2024EULAR_4421;    
    Most patients showed a gain in BMD over 3 years; vitamin D supplementation, female gender, taking previous preventive treatment and age >65 years seemed to be predictive of a better gain. Analysis of the reduction in fracture risk would also be interesting to research in this population.
  • ||||||||||  alendronate / Generic mfg.
    Preclinical, Journal:  Toxicity of Large and Small Surface-Engineered Upconverting Nanoparticles for In Vitro and In Vivo Bioapplications. (Pubmed Central) -  May 25, 2024   
    These included poly(ethylene glycol) (PEG) and poly(N,N-dimethylacrylamide-co-2-aminoethylacrylamide) [P(DMA-AEA)] terminated with an alendronate anchoring group, and poly(methyl vinyl ether-co-maleic acid) (PMVEMA)...An in vivo study indicated that L-UCNPs were eliminated from the body via the hepatobiliary route; L-UCNP@Ale-PEG particles were almost eliminated from the liver 96 h after intravenous application. Pilot fluorescence imaging confirmed the limited in vivo detection capabilities of the nanoparticles.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Review, Journal:  Utilization of Romosozumab in Primary Care. (Pubmed Central) -  May 24, 2024   
    Primary care physicians should consider romosozumab for patients at high fracture risk who are intolerant or have not responded to other pharmacological treatment. Further studies are needed to clarify the safety of cardiovascular events.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Bioinspired core-shell nanofiber drug-delivery system modulates osteogenic and osteoclast activity for bone tissue regeneration. (Pubmed Central) -  May 23, 2024   
    We fabricated core-shell P/PCL nanofibers using coaxial electrospinning, where alendronate (ALN) was incorporated into the core layer and hydroxyapatite (HA) into shell...Microcomputed tomography, histological examination, and immunohistochemical analysis collectively demonstrated that the PDA-functionalized core-shell PHA/PCL-ALN scaffolds exhibited exceptional osteogenesis-inducing and osteoclastogenesis-inhibiting effects. Finally, it may be concluded from our results that the bio-inspired surface-functionalized multifunctional, biomimetic and controlled release core-shell nanofiber provides a promising strategy to facilitate bone healing.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Cholesterol nanoarchaeosomes for alendronate targeted delivery as an anti-endothelial dysfunction agent. (Pubmed Central) -  May 22, 2024   
    Besides, while 10 mg/mL dexamethasone, 7.6 mM free ALN and ALN-loaded liposomes failed, 50 ?g/mL TL + 2.5 ?g/mL ALN (i.e., nanoARC-Chol(ALN)) reduced the IL-6 and IL-8 levels by, respectively, 75% and 65% in the mild and by, respectively, 60% and 40% in the pronounced inflammation model. This is the first report showing that the endocytosis of nanoARC-Chol(ALN) by HUVECs magnifies the anti-inflammatory activity of ALN even under conditions of intense irritation, not only surpassing that of free ALN but also that of dexamethasone.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal, HEOR:  Comparative effectiveness of Denosumab vs alendronate among postmenopausal women with osteoporosis. (Pubmed Central) -  May 16, 2024   
    In this cohort of almost half-a-million treatment-naive women with PMO, we observed clinically significant reductions in the risk of MOP, hip, NV, NHNV, and HV fractures for patients on denosumab compared with alendronate. Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Fosamax Fractures-Justice Has Not Been Served. (Pubmed Central) -  May 15, 2024   
    Patients who remained on denosumab for longer periods of time experienced greater reductions in fracture risk. No abstract available
  • ||||||||||  Prolia (denosumab) / Amgen
    Observational data, Retrospective data, Journal:  Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study. (Pubmed Central) -  May 9, 2024   
    Across Spanish PC, we observed a large gap in the treatment and follow-up of elderly subjects experiencing a fragility fracture. Our data highlights the urgent need to improve secondary fracture prevention in PC.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Journal:  3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. (Pubmed Central) -  May 2, 2024   
    3D-SHAPER analysis provides a novel technique for estimating changes in cortical and trabecular parameters from standard hip DXA images. These data add to the accumulating evidence that romosozumab improves hip bone density and structure, thereby contributing to the antifracture efficacy of the drug.
  • ||||||||||  Journal:  Spectrum of activity and mechanisms of azole-bisphosphonate synergy in pathogenic Candida. (Pubmed Central) -  May 2, 2024   
    Our research demonstrates the promising therapeutic potential of synergistically enhancing azoles with non-toxic, FDA-approved bisphosphonates. Repurposing bisphosphonates as antifungal synergists can bypass much of the drug development pipeline and accelerate the translation of azole-bisphosphonate combination therapy.
  • ||||||||||  acetylcysteine solution / Generic mfg.
    Preclinical, Journal:  S-Allylmercapto-N-Acetylcysteine (ASSNAC) Attenuates Osteoporosis in Ovariectomized (OVX) Mice. (Pubmed Central) -  Apr 27, 2024   
    These results portray the therapeutic potential of ASSNAC for the management of post-menopausal osteoporosis. Furthermore, ASSNAC ameliorates the Alendronate-associated oxidative stress, suggesting its potential to prevent Alendronate side effects as well as improve its bone-protective effect.
  • ||||||||||  Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Clinical, Retrospective data, Journal:  The sequential antifracturative treatment: a meta-analysis of randomized clinical trials. (Pubmed Central) -  Apr 24, 2024   
    In general, at 2?years after the switch from anabolic to antiresorptive drugs, a weighted BMD was increased at the lumbar spine, total hip, and femoral neck site. The Task Force formulated recommendations on sequential therapy, which is the first treatment with anabolic drugs or 'bone builders' in patients with very high or imminent risk of fracture.
  • ||||||||||  alendronate / Generic mfg.
    Preclinical, Journal:  PTH treatment before cyclic joint loading improves cartilage health and attenuates load-induced osteoarthritis development in mice. (Pubmed Central) -  Apr 23, 2024   
    We used parathyroid hormone (PTH) to modulate bone mass before OA initiation and alendronate (ALN) to inhibit bone remodeling during OA progression...With both treatments, the structural changes were associated with early modulation of immunoregulation and immunoresponse pathways that may contribute to disease mechanisms. Overall, our results demonstrate the potential of subchondral bone-modifying therapies to slow the progression of OA.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Dual ligand-targeted Pluronic P123 polymeric micelles enhance the therapeutic effect of breast cancer with bone metastases. (Pubmed Central) -  Apr 5, 2024   
    To improve the treatment efficacy, we developed Pluronic P123 (P123)-based polymeric micelles dually decorated with alendronate (ALN) and cancer-specific phage protein DMPGTVLP (DP-8) for targeted drug delivery to breast cancer bone metastases...In vivo experiments using a breast cancer bone metastasis nude model demonstrated increased accumulation of the micelles in the tumor region and considerable antitumor activity with no organ-specific histological damage and minimal systemic toxicity. In conclusion, our study provided strong evidence that these pH-sensitive dual ligand-targeted polymeric micelles may be a successful treatment strategy for breast cancer bone metastasis.
  • ||||||||||  methotrexate / Generic mfg.
    INSUFFICIENCY FRACTURES IN INFLAMMATORY ARTHRITIS PATIENTS  (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2578;    
    Methotrexate was stopped and she had Pamidronate...He was initially treated with Alendronate, then zoledronate and later teriparatide...She was treated with teriparatide, denosumab and then zoledronate...Stopping Methotrexate is helpful, but some patients may require anabolic and/or anti-resorptive drugs. Figure 1.
  • ||||||||||  Prolia (denosumab) / Amgen
    COMPARATIVE EFFECTIVENESS OF DENOSUMAB VERSUS BISPHOSPHONATES AMONG TREATMENT-EXPERIENCED POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN THE U.S. MEDICARE PROGRAM (Poster Tour 3) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1144;    
    66 years of age with prior history of treatment with an oral BP, who newly initiated Dmab (n~108,000), a different oral BP (alendronate, ibandronate, or risedronate; n=100,649), alendronate (Aln; n=53,165), or zoledronic acid (ZA; n=35,100) between Jan 1, 2012 to Dec 31, 2018 were followed from treatment initiation (index date) until the first instance of a fracture, treatment discontinuation (defined as the end of exposure + 60-day gap) or switch, Medicare disenrollment, death, end of available data (Dec 31, 2019), or 5 years post-index date. In a large cohort of treatment-experienced women with PMO, we observed robust, clinically meaningful reductions in the risk of hip, NV, NHNV, HV, and MOP fractures for patients on Dmab compared to oral BP, Aln, and ZA; greater reductions in fracture risk were observed with longer duration of exposure.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  An Injectable Magnesium-Based Cement Stimulated with NIR for Drug-Controlled Release and Osteogenic Potential. (Pubmed Central) -  Mar 26, 2024   
    It employed nanocontainers containing alendronate-loaded mesoporous silica nanoparticles, which had been surface-modified with polypyrrole to control drug release in response to near infrared (NIR) stimulation...Furthermore, ACMPC (NIR) group displayed good biocompatibility and osteogenesis capabilities, which also led to an increase in alkaline phosphatase activity, extracellular matrix mineralization, and the upregulation of osteogenic genes. This research has significant implications for developing multifunctional biomaterials and clinical application.
  • ||||||||||  enalapril / Generic mfg., alendronate / Generic mfg.
    Journal:  Importance about use of high-throughput sequencing in pediatric: case report of a patient with Fanconi-Bickel syndrome. (Pubmed Central) -  Mar 12, 2024   
    Overall, the use of an anabolic agent for the treatment of osteoporosis after BKP is better than the use of alendronate, even when treatment is initiated in the perioperative stage. The importance of knowing the etiology in rare genetic disease is essential, not only to determine individual and familial recurrence risk, but also to establish the treatment and prognosis; in this sense, access to a new genomic technology in low- and middle-income countries is essential to shorten the diagnostic odyssey.
  • ||||||||||  alendronate / Generic mfg.
    Journal:  Development of an injectable chitosan-based hydrogel containing nano-hydroxy-apatite and alendronate for MSC-based therapy. (Pubmed Central) -  Mar 11, 2024   
    Our synthetic approach utilized a BF3-etherate-mediated Friedel This study demonstrates the promising abilities of the ALN-loaded n-HAP scaffold to increase the proliferation, viability, and immunomodulatory capacity of ADSCs, elucidating new aspects of cell-material interactions that can be used for bone tissue regeneration/repair, and paving the path of future research in developing new approaches for MSC- based therapy.